Progressive Supranuclear Palsy Diagnostic Methods

Overview

Progressive Supranuclear Palsy (PSP) is a 4R-tauopathy characterized by progressive postural instability, vertical supranuclear gaze palsy, and cognitive impairment. Accurate diagnosis remains challenging, particularly in early disease stages, due to clinical overlap with Parkinson's disease (PD), Corticobasal Syndrome (CBS), and other parkinsonian disorders. This page details current diagnostic approaches, including clinical criteria, imaging biomarkers, CSF analysis, and differential diagnosis.

Clinical Diagnostic Criteria

Movement Disorder Society-PSP Criteria (MDS-PSP 2017)

The MDS-PSP criteria represent the current standard for PSP diagnosis, providing four phenotypic subtypes with varying levels of diagnostic certainty:

| Level | Description |
|-------|-------------|
| Probable PSP | Core clinical features present with no alternative explanation |
| Possible PSP | Core or suggestive features present but with some uncertainty |
| Suggestive of PSP | Fewer or less specific features, requiring imaging support |
| Laboratory-supported PSP | Specific biomarker findings supporting diagnosis |

Core Clinical Features

Vertical supranuclear gaze palsy (VSGP) — Cardinal feature; downward gaze impairment is most specific

Postural instability with falls — Within first year of symptoms predicts PSP-P (parkinsonian variant)

Progressive gait freezing — Early gait ignition failure and freezing

Cortical dysfunction — Frontal lobe signs including apathy, disinhibition, executive dysfunction

Suggestive Features

...

Overview

Progressive Supranuclear Palsy (PSP) is a 4R-tauopathy characterized by progressive postural instability, vertical supranuclear gaze palsy, and cognitive impairment. Accurate diagnosis remains challenging, particularly in early disease stages, due to clinical overlap with Parkinson's disease (PD), Corticobasal Syndrome (CBS), and other parkinsonian disorders. This page details current diagnostic approaches, including clinical criteria, imaging biomarkers, CSF analysis, and differential diagnosis.

Clinical Diagnostic Criteria

Movement Disorder Society-PSP Criteria (MDS-PSP 2017)

The MDS-PSP criteria represent the current standard for PSP diagnosis, providing four phenotypic subtypes with varying levels of diagnostic certainty:

| Level | Description |
|-------|-------------|
| Probable PSP | Core clinical features present with no alternative explanation |
| Possible PSP | Core or suggestive features present but with some uncertainty |
| Suggestive of PSP | Fewer or less specific features, requiring imaging support |
| Laboratory-supported PSP | Specific biomarker findings supporting diagnosis |

Core Clinical Features

Vertical supranuclear gaze palsy (VSGP) — Cardinal feature; downward gaze impairment is most specific

Postural instability with falls — Within first year of symptoms predicts PSP-P (parkinsonian variant)

Progressive gait freezing — Early gait ignition failure and freezing

Cortical dysfunction — Frontal lobe signs including apathy, disinhibition, executive dysfunction

Suggestive Features

• Early dysphagia and dysarthria
• Early cognitive impairment with frontal lobe pattern
• Levodopa-unresponsive parkinsonism
• Myoclonus (especially in PSP-CBS)
• Alien limb phenomena

Clinical Subtypes

| Subtype | Core Features | Typical Presentation |
|---------|---------------|---------------------|
| PSP-Richardson's (PSP-RS) | VSGP + postural instability | Classic Richardson's syndrome |
| PSP-Parkinsonism (PSP-P) | Asymmetric onset, tremor, levodopa response | May resemble PD initially |
| PSP-Pure Akinesia with Gait Freezing (PSP-PAGF) | Gait freezing without VSGP | Longer disease duration |
| PSP-Corticobasal (PSP-CBS) | Cortical sensory loss, apraxia | Overlaps with CBS |
| PSP-Frontal (PSP-F) | Predominant frontal dysfunction | Behavioral variant |
| Primary Progressive Aphasia (PSP-PPA) | Language dysfunction | Rare variant |

Imaging Biomarkers

Magnetic Resonance Imaging

Conventional MRI Findings

• Midbrain atrophy: "Hummingbird sign" on midsagittal views
• Superior cerebellar peduncle atrophy: "Mickey Mouse sign"
• Third ventricle enlargement
• Frontotemporal cortical atrophy

Quantitative MRI Techniques

• MR planimetry: Midbrain/pons area ratio <0.52 suggests PSP
• Magnetic Resonance Parkinsonism Index (MRPI): Elevated in PSP vs. PD
• Free water imaging: Elevated in substantia nigra and pedunculopontine nucleus

SWI (Susceptibility-Weighted Imaging)

• [Tau](/proteins/tau)-related changes: Reduced contrast in red nucleus and substantia nigra
• Iron deposition patterns: Differentiate PSP from PD

Nuclear Medicine Imaging

DAT Imaging (DaTscan/I-123 FP-CIT)

• Presynaptic dopamine transporter loss: Typically more severe in PSP than PD
• Pattern analysis: Caudate involvement more prominent in PSP

FDG-PET

• Metabolic patterns: Hypometabolism in prefrontal [cortex](/brain-regions/cortex), brainstem, and cerebellar hemispheres
• Differential patterns: PSP shows midbrain and frontal hypometabolism; PD shows putaminal changes

Tau PET Imaging

• F-18 AV-1451 (Flortaucipir): Binds to paired helical filament tau
• Preliminary findings: Elevated binding in PSP brainstem and subcortical structures
• Clinical utility: Currently research use only

CSF Biomarkers

Established Markers

| Biomarker | PSP Finding | Clinical Utility |
|-----------|-------------|------------------|
| [Neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain (NfL) | Elevated | High sensitivity for neurodegeneration |
| Total tau (t-tau) | Normal to mildly elevated | Differentiates from AD |
| Phosphorylated tau (p-tau) | Normal or mildly elevated | Distinguishes from AD |
| [Alpha-synuclein](/proteins/alpha-synuclein) | Normal | Rules out MSA-P, PD |
| [Beta-amyloid](/proteins/amyloid-beta) 1-42 | Normal | Rules out AD comorbidity |

Emerging Biomarkers

• Tau oligomers: Elevated in PSP vs. controls
• Neurogranin: Marker of synaptic dysfunction
• YKL-40 (Chitinase-3-like protein 1): Astrocytic activation marker
• [TREM2](/proteins/trem2): Microglial activation marker

Differential Diagnosis

Parkinson's Disease (PD)

| Feature | PSP | PD |
|---------|-----|----|
| Eye movements | VSGP early | Late or absent |
| Postural instability | Early (within 1 year) | Late (after 5+ years) |
| Tremor | Less common | Common, resting tremor |
| Levodopa response | Poor | Good initially |
| Progression | Rapid | Slow |

Corticobasal Syndrome (CBS)

• Overlap: PSP-CBS phenotype shares features
• Key differences: Asymmetric onset, apraxia, cortical sensory loss favor CBS
• Tau pathology: Both are 4R-tauopathies; post-mortem required for definitive diagnosis

Multiple System Atrophy (MSA-P)

• Autonomic dysfunction: More severe in MSA
• Cerebellar signs: Favor MSA-C variant
• Imaging: Hot cross bun sign in MSA

Alzheimer's Disease

• Memory impairment: More prominent in AD
• Amyloid biomarkers: Positive in AD, negative in PSP
• Tau PET: Different binding patterns

Diagnostic Workflow

Treatment Implications

While no disease-modifying therapy exists, accurate diagnosis is crucial for:

• Prognostic counseling: PSP progresses more rapidly than PD
• Clinical trial eligibility: Many trials require specific PSP diagnoses
• Symptomatic management: Different approaches for PSP vs. PD
• Care planning: Early fall prevention, swallowing assessment

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Related Pages

• [Progressive Supranuclear Palsy (PSP)](/diseases/progressive-supranuclear-palsy)
• [Tauopathies](/proteins/tau)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Corticobasal Syndrome - Disease Mechanisms](/mechanisms)
• [4R-Tau](/proteins/tau)

References

[Hoglinger et al., MDS diagnostic criteria for PSP (2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/28440524/)

[Litvan et al., PSP: Current concepts and clinical approach (n.d.)](https://pubmed.ncbi.nlm.nih.gov/33436543/)

[Costanzi-Nguyen et al., MRI biomarkers in PSP (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35674489/)

[Poewe et al., Diagnosis and management of atypical parkinsonisms (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35877012/)

[Beyer et al., CSF neurofilament light chain in PSP (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/33962741/)

[Armstrong et al., Criteria for corticobasal syndrome (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/19560099/)

[Jankovic et al., Parkinson's disease: Motor and non-motor symptoms (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37640367/)

[Respondek et al., The progression of regional tau pathology in PSP (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/33201234/)